StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

A number of other research analysts also recently commented on CTLT. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a report on Friday, June 28th. Stephens reaffirmed an equal weight rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of Hold and a consensus target price of $55.65.

Catalent Trading Up 0.6 %

Shares of Catalent stock opened at $56.51 on Friday. The firm has a market cap of $10.23 billion, a price-to-earnings ratio of -9.26 and a beta of 1.16. The business has a 50-day moving average price of $55.58 and a 200-day moving average price of $54.18. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. Catalent has a twelve month low of $31.80 and a twelve month high of $60.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Equities research analysts anticipate that Catalent will post -0.17 EPS for the current fiscal year.

Insiders Place Their Bets

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.31% of the stock is owned by insiders.

Institutional Trading of Catalent

Several institutional investors have recently added to or reduced their stakes in CTLT. Nomura Holdings Inc. lifted its stake in Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the last quarter. Norges Bank purchased a new position in shares of Catalent during the fourth quarter worth approximately $116,021,000. Ameriprise Financial Inc. increased its position in shares of Catalent by 65.9% during the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock worth $158,601,000 after acquiring an additional 1,384,313 shares during the period. Capital World Investors increased its position in shares of Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after acquiring an additional 1,098,474 shares during the period. Finally, Magnetar Financial LLC purchased a new position in shares of Catalent during the first quarter worth approximately $56,429,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.